Zobrazeno 1 - 10
of 22
pro vyhledávání: '"David M Briere"'
Autor:
Jill Hallin, Vickie Bowcut, Andrew Calinisan, David M. Briere, Lauren Hargis, Lars D. Engstrom, Jade Laguer, James Medwid, Darin Vanderpool, Ella Lifset, David Trinh, Natalie Hoffman, Xiaolun Wang, J. David Lawson, Robin J. Gunn, Christopher R. Smith, Nicole C. Thomas, Matthew Martinson, Alex Bergstrom, Francis Sullivan, Karyn Bouhana, Shannon Winski, Leo He, Julio Fernandez-Banet, Adam Pavlicek, Jacob R. Haling, Lisa Rahbaek, Matthew A. Marx, Peter Olson, James G. Christensen
Publikováno v:
Nature Medicine. 28:2171-2182
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d677a7e099fb8459d3aaad7bbf29b468
https://doi.org/10.1038/s41591-022-02007-7
https://doi.org/10.1038/s41591-022-02007-7
Autor:
John M. Ketcham, Jacob Haling, Shilpi Khare, Vickie Bowcut, David M. Briere, Aaron C. Burns, Robin J. Gunn, Anthony Ivetac, Jon Kuehler, Svitlana Kulyk, Jade Laguer, J. David Lawson, Krystal Moya, Natalie Nguyen, Lisa Rahbaek, Barbara Saechao, Christopher R. Smith, Niranjan Sudhakar, Nicole C. Thomas, Laura Vegar, Darin Vanderpool, Xiaolun Wang, Larry Yan, Peter Olson, James G. Christensen, Matthew A. Marx
Publikováno v:
Journal of Medicinal Chemistry. 65:9678-9690
SOS1 is one of the major guanine nucleotide exchange factors that regulates the ability of KRAS to cycle through its "on" and "off" states. Disrupting the SOS1:KRAS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::afe52dccfc91d77da8d18ff2be215969
https://doi.org/10.1021/acs.jmedchem.2c00741
https://doi.org/10.1021/acs.jmedchem.2c00741
Autor:
Peter Olson, James G. Christensen, Kwok-Kin Wong, Adam Pavlicek, Julio Fernandez-Banet, Sole Gatto, Jill Hallin, Lars D. Engstrom, Jiehui Deng, David H. Peng, Lauren Hargis, Ruth Aranda, Niranjan Sudhakar, Andrew Calinisan, Shuai Li, David M. Briere
Supplementary Material
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89313461352dbe1920a2daf9ea2d10c3
https://doi.org/10.1158/1535-7163.22522489
https://doi.org/10.1158/1535-7163.22522489
Autor:
James G. Christensen, Peter Olson, Pasi A. Jänne, Kyriakos P. Papadopoulos, Piro Lito, Sai-Hong Ignatius Ou, Melissa L. Johnson, Igor I. Rybkin, Matthew A. Marx, Douglas P. Cassidy, Emanuel F. Patricoin, Elisa Baldelli, Mariaelena Pierobon, Jeremy Barton, Richard C. Chao, Karen Velastagui, Adam Pavlicek, Julio Fernandez-Banet, Sole Gatto, Yaohua Xue, Guy P. Vigers, John P. Fischer, Jay B. Fell, Michael R. Burkard, Joshua A. Ballard, Brian R. Baer, Vickie Bowcut, Niranjan Sudhakar, David M. Briere, Ruth Aranda, Andrew Calinisan, Lauren Hargis, Lars D. Engstrom, Jill Hallin
Supplementary Composite Figure File
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::095624453d8ad8530fb345958c4cd8b6
https://doi.org/10.1158/2159-8290.22535530.v1
https://doi.org/10.1158/2159-8290.22535530.v1
Autor:
Peter Olson, James G. Christensen, Kwok-Kin Wong, Adam Pavlicek, Julio Fernandez-Banet, Sole Gatto, Jill Hallin, Lars D. Engstrom, Jiehui Deng, David H. Peng, Lauren Hargis, Ruth Aranda, Niranjan Sudhakar, Andrew Calinisan, Shuai Li, David M. Briere
KRASG12C inhibitors, including MRTX849, are promising treatment options for KRAS-mutant non–small cell lung cancer (NSCLC). PD-1 inhibitors are approved in NSCLC; however, strategies to enhance checkpoint inhibitor therapy (CIT) are needed. KRASG12
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0679ee9794421d5e87ada96097d171a6
https://doi.org/10.1158/1535-7163.c.6543400.v1
https://doi.org/10.1158/1535-7163.c.6543400.v1
Autor:
Peter Olson, James G. Christensen, Kwok-Kin Wong, Adam Pavlicek, Julio Fernandez-Banet, Sole Gatto, Jill Hallin, Lars D. Engstrom, Jiehui Deng, David H. Peng, Lauren Hargis, Ruth Aranda, Niranjan Sudhakar, Andrew Calinisan, Shuai Li, David M. Briere
Figures S1-S7
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ceca5b28312dd8892d9b8d8ba17873c
https://doi.org/10.1158/1535-7163.22522492
https://doi.org/10.1158/1535-7163.22522492
Autor:
James G. Christensen, Peter Olson, Pasi A. Jänne, Kyriakos P. Papadopoulos, Piro Lito, Sai-Hong Ignatius Ou, Melissa L. Johnson, Igor I. Rybkin, Matthew A. Marx, Douglas P. Cassidy, Emanuel F. Patricoin, Elisa Baldelli, Mariaelena Pierobon, Jeremy Barton, Richard C. Chao, Karen Velastagui, Adam Pavlicek, Julio Fernandez-Banet, Sole Gatto, Yaohua Xue, Guy P. Vigers, John P. Fischer, Jay B. Fell, Michael R. Burkard, Joshua A. Ballard, Brian R. Baer, Vickie Bowcut, Niranjan Sudhakar, David M. Briere, Ruth Aranda, Andrew Calinisan, Lauren Hargis, Lars D. Engstrom, Jill Hallin
Despite decades of research, efforts to directly target KRAS have been challenging. MRTX849 was identified as a potent, selective, and covalent KRASG12C inhibitor that exhibits favorable drug-like properties, selectively modifies mutant cysteine 12 i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dd866fa6fe03bc0849986ce88d5870c4
https://doi.org/10.1158/2159-8290.c.6547879.v1
https://doi.org/10.1158/2159-8290.c.6547879.v1
Autor:
Christopher R. Smith, Ruth Aranda, Thomas P. Bobinski, David M. Briere, Aaron C. Burns, James G. Christensen, Jeffery Clarine, Lars D. Engstrom, Robin J. Gunn, Anthony Ivetac, Ronald Jean-Baptiste, John M. Ketcham, Masakazu Kobayashi, Jon Kuehler, Svitlana Kulyk, J. David Lawson, Krystal Moya, Peter Olson, Lisa Rahbaek, Nicole C. Thomas, Xiaolun Wang, Laura M. Waters, Matthew A. Marx
Publikováno v:
Journal of Medicinal Chemistry. 65:1749-1766
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6807ba018e034c41898a959b92d453dc
https://doi.org/10.1021/acs.jmedchem.1c01900
https://doi.org/10.1021/acs.jmedchem.1c01900
Autor:
Xiaolun Wang, Shelley Allen, James F. Blake, Vickie Bowcut, David M. Briere, Andrew Calinisan, Joshua R. Dahlke, Jay B. Fell, John P. Fischer, Robin J. Gunn, Jill Hallin, Jade Laguer, J. David Lawson, James Medwid, Brad Newhouse, Phong Nguyen, Jacob M. O’Leary, Peter Olson, Spencer Pajk, Lisa Rahbaek, Mareli Rodriguez, Christopher R. Smith, Tony P. Tang, Nicole C. Thomas, Darin Vanderpool, Guy P. Vigers, James G. Christensen, Matthew A. Marx
Publikováno v:
Journal of Medicinal Chemistry. 65:3123-3133
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0a806650aaec5c7d35ae8ff6555c3535
https://doi.org/10.1021/acs.jmedchem.1c01688
https://doi.org/10.1021/acs.jmedchem.1c01688
Autor:
Laura Waters, Ruth Aranda, Krystal Moya, Victoria Bowcut, David Trinh, Allan Hebbert, Leo He, Laura D. Hover, Julio Fernandez-Banet, Jill Hallin, David M. Briere, James G. Christensen, Peter A. Olson, Lars D. Engstrom
Publikováno v:
Cancer Research. 83:2779-2779
Previous studies identified PRMT5 as a synthetic lethal target for cancers harboring homozygous deletion of the MTAP gene (MTAP del) whereby accumulation of MTA, the MTAP substrate, partially inhibits PRMT5 activity leading to an increased dependency
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ea9de851829c421ee9f14082938b4050
https://doi.org/10.1158/1538-7445.am2023-2779
https://doi.org/10.1158/1538-7445.am2023-2779